Molecular signatures of neoadjuvant endocrine therapy for breast cancer: Characteristics of response or intrinsic resistance

Breast Cancer Research and Treatment

Volumn 112, Issue 3, 2008, Pages 475-488

  Harvell, Djuana M E ^a   Spoelstra, Nicole S ^a   Singh, Meenakshi ^a   McManaman, James L ^b   Finlayson, Christina ^a   Phang, Tzu ^a   Trapp, Susan ^a   Hunter, Lawrence ^a   Dye, Wendy W ^a   Borges, Virginia F ^a   Elias, Anthony ^a   Horwitz, Kathryn B ^a   Richer, Jennifer K ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptors; Aromatase inhibitors; Breast cancer; Estrogen receptors; Expression profiling; Lipogenic phenotype; Neoadjuvant endocrine therapy; Tamoxifen

Indexed keywords

ANDROGEN RECEPTOR; ANTIESTROGEN; AROMATASE INHIBITOR; COMPLEMENTARY DNA; COMPLEMENTARY RNA; ESTROGEN RECEPTOR; EXEMESTANE; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN S 100; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; ULTRASOUND; WESTERN BLOTTING;

BREAST NEOPLASMS; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; RECEPTORS, ESTROGEN; S100 PROTEINS; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 56549102420     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9897-4     Document Type: Article

References (61)

1. JN Ingle 2005 Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings Clin Cancer Res 11 900s 905s
2. EP Winer C Hudis HJ Burstein 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol 23 619 629
3. A Howell J Cuzick M Baum 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62
4. IE Smith M Dowsett SR Ebbs 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108 5116
5. M Dowsett J Cuzick A Howell I Jackson 2001 Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial Br J Cancer 85 317 324
6. M Dowsett BP Haynes 2003 Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen J Steroid Biochem Mol Biol 86 255 263
7. D Jelovac L Macedo V Handratta 2004 Effects of exemestane and tamoxifen in a postmenopausal breast cancer model Clin Cancer Res 10 7375 7381
8. T Zaccheo D Giudici E Di Salle 1993 Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats J Steroid Biochem Mol Biol 44 677 680
9. PR Hutson RR Love TC Havighurst E Rogers JF Cleary 2005 Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer Clin Cancer Res 11 8722 8727
10. RR Love PR Hutson TC Havighurst JF Cleary 2005 Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer Clin Cancer Res 11 1500 1503
11. E Rivera V Valero D Francis 2004 Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen Clin Cancer Res 10 1943 1948
12. NS Spoelstra NG Manning Y Higashi 2006 The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers Cancer Res 66 3893 3902
13. TD Russell CA Palmer DJ Orlicky 2007 Cytoplasmic lipid droplet accumulation in developing mammary epithelial cells: roles of adipophilin and lipid metabolism J Lipid Res 48 1463 1475
14. C Londos DL Brasaemle J Gruia-Gray 1995 Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells Biochem Soc Trans 23 611 615
15. DL Brasaemle T Barber NE Wolins G Serrero EJ Blanchette-Mackie C Londos 1997 Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein J Lipid Res 38 2249 2263
16. JK Richer BM Jacobsen NG Manning MG Abel DM Wolf KB Horwitz 2002 Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells J Biol Chem 277 5209 5218
17. KB Horwitz WL McGuire 1975 Predicting response to endocrine therapy in human breast cancer: a hypothesis Science 189 726 727
18. WL McGuire GM Clark 1983 The prognostic role of progesterone receptors in human breast cancer Semin Oncol 10 2 6
19. X Cui R Schiff G Arpino CK Osborne AV Lee 2005 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 7721 7735
20. CK Osborne R Schiff G Arpino AS Lee VG Hilsenbeck 2005 Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy Breast 14 458 465
21. M Singh KE Capocelli JL Marks RB Schleicher CA Finlayson PA Seligman 2005 Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer Appl Immunohistochem Mol Morphol 13 147 156
22. R Burcombe GD Wilson M Dowsett 2006 Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer Breast Cancer Res 8 R31
23. MJ Ellis Y Tao O Young 2006 Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole J Clin Oncol 24 3019 3025
24. M Dowsett IE Smith SR Ebbs 2006 Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer Clin Cancer Res 12 1024s 1030s
25. AG Mackay A Urruticoechea JM Dixon 2007 Molecular response to aromatase inhibitor treatment in primary breast cancer Breast Cancer Res 9 R37
26. XH Li DE Ong 2003 Cellular retinoic acid-binding protein II gene expression is directly induced by estrogen, but not retinoic acid, in rat uterus J Biol Chem 278 35819 35825
27. LA McPherson GW Woodfield RJ Weigel 2007 AP2 transcription factors regulate expression of CRABPII in hormone responsive breast carcinoma J Surg Res 138 71 78
28. SS Sheth JS Bodnar A Ghazalpour 2006 Hepatocellular carcinoma in Txnip-deficient mice Oncogene 25 3528 3536
29. SF Goldberg ME Miele N Hatta 2003 Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP Cancer Res 63 432 440
30. BJ Deroo SC Hewitt SD Peddada KS Korach 2004 Estradiol regulates the thioredoxin antioxidant system in the mouse uterus Endocrinology 145 5485 5492
31. JV Swinnen K Brusselmans G Verhoeven 2006 Increased lipogenesis in cancer cells: new players, novel targets Curr Opin Clin Nutr Metab Care 9 358 365
32. T Suzuki S Hayashi Y Miki 2006 Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions Endocr Relat Cancer 13 233 250
33. WB Kinlaw JL Quinn WA Wells C Roser-Jones JT Moncur 2006 Spot 14: a marker of aggressive breast cancer and a potential therapeutic target Endocrinology 147 4048 4055
34. WA Wells GN Schwartz PM Morganelli BF Cole JJ Gibson WB Kinlaw 2006 Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker Breast Cancer Res Treat 98 231 240
35. CM Perou T Sorlie MB Eisen 2000 Molecular portraits of human breast tumours Nature 406 747 752
36. C Londos DL Brasaemle CJ Schultz JP Segrest AR Kimmel 1999 Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells Semin Cell Dev Biol 10 51 58
37. JL McManaman ME Reyland EC Thrower 2006 Secretion and fluid transport mechanisms in the mammary gland: comparisons with the exocrine pancreas and the salivary gland J Mammary Gland Biol Neoplasia 11 249 268
38. AS Doane M Danso P Lal 2006 An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen Oncogene 25 3994 4008
39. P Farmer H Bonnefoi V Becette 2005 Identification of molecular apocrine breast tumours by microarray analysis Oncogene 24 4660 4671
40. KT Morris S Toth-Fejel J Schmidt WS Fletcher RF Pommier 2001 High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy Surgery 130 947 953
41. E Bajetta N Zilembo C Noberasco 1997 The minimal effective exemestane dose for endocrine activity in advanced breast cancer Eur J Cancer 33 587 591
42. JA Garcia-Velasco L Moreno A Pacheco 2005 The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study Fertil Steril 84 82 87
43. EA Ariazi A Leitao TI Oprea 2007 Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen Mol Cancer Ther 6 2817 2827
44. F Andre C Hatzis K Anderson 2007 Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer Clin Cancer Res 13 2061 2067
45. A Brodie G Sabnis L Macedo 2007 Xenograft models for aromatase inhibitor studies J Steroid Biochem Mol Biol 106 119 124
46. JW Martens I Nimmrich T Koenig 2005 Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer Cancer Res 65 4101 4117
47. SK Chatterjee BR Zetter 2005 Cancer biomarkers: knowing the present and predicting the future Future Oncol 1 37 50
48. S de Silva Rudland L Martin C Roshanlall 2006 Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer Clin Cancer Res 12 1192 1200
49. A Martinetti E Bajetta L Ferrari 2004 Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole Endocr Relat Cancer 11 771 779
50. M Foldi E Stickeler L Bau 2007 Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer Oncol Rep 17 841 845
51. ID Guerreiro Da Silva YF Hu IH Russo 2000 S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo Int J Oncol 16 231 240
52. J Russo YF Hu ID Silva IH Russo 2001 Cancer risk related to mammary gland structure and development Microsc Res Tech 52 204 223
53. AP Schor FM Carvalho C Kemp ID Silva J Russo 2006 S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast Oncol Rep 15 3 6
54. M Koltzscher C Neumann S Konig V Gerke 2003 Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P Mol Biol Cell 14 2372 2384
55. S Mousses L Bubendorf U Wagner 2002 Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays Cancer Res 62 1256 1260
56. T Arumugam DM Simeone K Van Golen CD Logsdon 2005 S100P promotes pancreatic cancer growth, survival, and invasion Clin Cancer Res 11 5356 5364
57. A Taguchi DC Blood G del Toro 2000 Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases Nature 405 354 360
58. M Nowotny M Spiechowicz B Jastrzebska A Filipek K Kitagawa J Kuznicki 2003 Calcium-regulated interaction of Sgt1 with S100A6 (calcyclin) and other S100 proteins J Biol Chem 278 26923 26928
59. SE Dowen T Crnogorac-Jurcevic R Gangeswaran 2005 Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer Am J Pathol 166 81 92
60. JD Bray S Jelinsky R Ghatge 2005 Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells J Steroid Biochem Mol Biol 97 328 341
61. VN Kristensen T Sorlie J Geisler 2005 Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer J Steroid Biochem Mol Biol 95 105 111